Cargando…

Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician

OBJECTIVE: Radiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations...

Descripción completa

Detalles Bibliográficos
Autores principales: Piras, Antonio, Boldrini, Luca, Menna, Sebastiano, Venuti, Valeria, Pernice, Gianfranco, Franzese, Ciro, Angileri, Tommaso, Daidone, Antonino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633531/
https://www.ncbi.nlm.nih.gov/pubmed/34868976
http://dx.doi.org/10.3389/fonc.2021.761393
_version_ 1784607948400492544
author Piras, Antonio
Boldrini, Luca
Menna, Sebastiano
Venuti, Valeria
Pernice, Gianfranco
Franzese, Ciro
Angileri, Tommaso
Daidone, Antonino
author_facet Piras, Antonio
Boldrini, Luca
Menna, Sebastiano
Venuti, Valeria
Pernice, Gianfranco
Franzese, Ciro
Angileri, Tommaso
Daidone, Antonino
author_sort Piras, Antonio
collection PubMed
description OBJECTIVE: Radiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies. MATERIALS AND METHODS: A systematic database search was performed on PubMed and Embase according to Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Original studies, case series, and case reports describing the use of HFRT (with at least 2.2 Gy fractions) in patients with mean age ≥65 years were included. The analysis was based on the type of study, number of patients, mean age, tumor site, histology, performance status (PS), RT details, concomitant chemotherapy (CT), and described clinical outcomes. All the reported doses have been calculated in equivalent dose in 2 Gy fractions (EQD2) and biologically effective dose (BED) using α/β = 10 Gy or α/β = 12 Gy. RESULTS: We selected 17 papers that met the inclusion criteria and divided them in 4 categories: 6 articles analyze HFRT performed twice daily in repeated cycles, 3 once a day in repeated cycles, 4 in alternative days, and the last 4 in consecutive days. CONCLUSION: HFRT seems to be a good treatment with an acceptable prolonged disease control. In older patients fit for radical treatments, a 55 Gy in 20 fractions regimen can be proposed as a valid alternative to the standard fractionated RT, but there are a multitude of hypofractionated regimens, ranging from single fraction, quad shot, and 1-, 2-, 3-, 4-, and 5-week schedules that all may be appropriate. The correct regimen for a patient depends on many factors, and it represents the result of a more specific and complex decision.
format Online
Article
Text
id pubmed-8633531
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86335312021-12-02 Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician Piras, Antonio Boldrini, Luca Menna, Sebastiano Venuti, Valeria Pernice, Gianfranco Franzese, Ciro Angileri, Tommaso Daidone, Antonino Front Oncol Oncology OBJECTIVE: Radiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies. MATERIALS AND METHODS: A systematic database search was performed on PubMed and Embase according to Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) guidelines. Original studies, case series, and case reports describing the use of HFRT (with at least 2.2 Gy fractions) in patients with mean age ≥65 years were included. The analysis was based on the type of study, number of patients, mean age, tumor site, histology, performance status (PS), RT details, concomitant chemotherapy (CT), and described clinical outcomes. All the reported doses have been calculated in equivalent dose in 2 Gy fractions (EQD2) and biologically effective dose (BED) using α/β = 10 Gy or α/β = 12 Gy. RESULTS: We selected 17 papers that met the inclusion criteria and divided them in 4 categories: 6 articles analyze HFRT performed twice daily in repeated cycles, 3 once a day in repeated cycles, 4 in alternative days, and the last 4 in consecutive days. CONCLUSION: HFRT seems to be a good treatment with an acceptable prolonged disease control. In older patients fit for radical treatments, a 55 Gy in 20 fractions regimen can be proposed as a valid alternative to the standard fractionated RT, but there are a multitude of hypofractionated regimens, ranging from single fraction, quad shot, and 1-, 2-, 3-, 4-, and 5-week schedules that all may be appropriate. The correct regimen for a patient depends on many factors, and it represents the result of a more specific and complex decision. Frontiers Media S.A. 2021-11-12 /pmc/articles/PMC8633531/ /pubmed/34868976 http://dx.doi.org/10.3389/fonc.2021.761393 Text en Copyright © 2021 Piras, Boldrini, Menna, Venuti, Pernice, Franzese, Angileri and Daidone https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Piras, Antonio
Boldrini, Luca
Menna, Sebastiano
Venuti, Valeria
Pernice, Gianfranco
Franzese, Ciro
Angileri, Tommaso
Daidone, Antonino
Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title_full Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title_fullStr Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title_full_unstemmed Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title_short Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician
title_sort hypofractionated radiotherapy in head and neck cancer elderly patients: a feasibility and safety systematic review for the clinician
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633531/
https://www.ncbi.nlm.nih.gov/pubmed/34868976
http://dx.doi.org/10.3389/fonc.2021.761393
work_keys_str_mv AT pirasantonio hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT boldriniluca hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT mennasebastiano hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT venutivaleria hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT pernicegianfranco hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT franzeseciro hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT angileritommaso hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician
AT daidoneantonino hypofractionatedradiotherapyinheadandneckcancerelderlypatientsafeasibilityandsafetysystematicreviewfortheclinician